Be Bio Closes $130 Million Financing To Pioneer Engineered B Cells, A New Class Of Cellular Medicines
Amount Raised
$130 Million
Round Type
Funding Round
CambridgeInformation TechnologyBiotechnologySoftwareData And AnalyticsScience And EngineeringDescription
Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM), today announced the closing of a $130 million financing, bringing the total investment in the Company to over $180 million. The proceeds will advance Be Bio’s proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates toward the clinic. The Series B was led by ARCH Venture Partners and joined by Bristol Myers Squibb and other new investors, alongside existing investors including Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and Takeda Ventures.
Quick answer
Be Biopharma raised $130 Million in a Funding Round round, dated April 14, 2022. Be Biopharma is based in Cambridge, Massachusetts, United States.
- How much did Be Biopharma raise?
- Be Biopharma raised $130 Million in a Funding Round round on April 14, 2022.
- What does Be Biopharma do?
- Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions.
- Where is Be Biopharma based and how big is it?
- Be Biopharma is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Be Biopharma?
- Fundz holds 1 contact at Be Biopharma. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Data And Analytics and Science And Engineering around the same time
Companies in the same sectors as Be Biopharma that raised within 45 days of this round, from Fundz verified event records.
- IMPLICITY raised $23M (Funding Round) on April 27, 2022.
- Ensem Therapeutics raised $67M (Series A) on April 6, 2022.
- Zephyr AI, Inc. raised $18M on April 4, 2022.
- Zephyr AI, Inc. raised $19M (Seed) on March 30, 2022.
- Nucleai raised $33M (Series B) on March 22, 2022.
- Anduril raised $1.2B (Funding Round) on May 24, 2022.
Who to call at Be Biopharma, and when
A new round usually means Be Biopharma is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Be Biopharma raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Be Biopharma, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Be Biopharma. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Be Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Be Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.